Jul 10, 2026 · 13 min · 11 segments
Editor's Summary by Linda Brubaker, MD, and Preeti Malani, MD, MSJ, Deputy Editors of JAMA, the Journal of the American Medical Association, for articles published from…
Preeti MalaniHostLinda BrubakerHostPreeti, let's get started with the research article that explores a novel clinical approach for patients with advanced lung cancer.
Lung cancer remains a leading cause of cancer-related death worldwide, and the classic teaching has been that lung transplantation is not an option for patients with advanced stage four non-small cell lung cancer, even when the cancer is confined only to the lungs.
This has largely been based on data from earlier studies, but these studies predated modern cancer therapies, current staging standards, and also used surgical techniques that could have promoted cancer spread.
In a prospective single center registry study, Dr. Bharath and colleagues followed seventeen patients with advanced non-small cell lung cancer who underwent bilateral lung transplantation using a dissemination minimizing surgical technique.
That means using certain techniques like early pulmonary vein control and extensive irrigation to limit spread of tumor cells during surgery.
Compared with eighty-one otherwise eligible patients who received nonsurgical medical management, those who underwent transplantation saw a significant difference.
One-year survival was one hundred percent versus just forty-one percent in the medical management group.
The surgical group's early post-transplant survival was also non-inferior to that of three hundred and six patients without cancer who received lung transplants.
So for this very select patient group, lung transplantation was associated with longer early survival.
While broader application will need much more data, both in terms of longer term follow-up and quality of life assessments, this approach may eventually offer a new treatment option to a group of patients with historically few options.
In an accompanying editorial, Doctors Dalen and Govinda highlight both the promise and perils of this approach.
They point out that while these results are encouraging, the transplant candidates were a carefully selected subset, and any move toward wider adoption needs multi-center randomized trials, long-term outcomes, and a careful look at organ donor stewardship.
Preeti, let's get started with the research article that explores a novel clinical approach for patients with advanced lung cancer.
Lung cancer remains a leading cause of cancer-related death worldwide, and the classic teaching has been that lung transplantation is not an option for patients with advanced stage four non-small cell lung cancer, even when the cancer is confined only to the lungs.
This has largely been based on data from earlier studies, but these studies predated modern cancer therapies, current staging standards, and also used surgical techniques that could have promoted cancer spread.
In a prospective single center registry study, Dr. Bharath and colleagues followed seventeen patients with advanced non-small cell lung cancer who underwent bilateral lung transplantation using a dissemination minimizing surgical technique.
That means using certain techniques like early pulmonary vein control and extensive irrigation to limit spread of tumor cells during surgery.
Compared with eighty-one otherwise eligible patients who received nonsurgical medical management, those who underwent transplantation saw a significant difference.
One-year survival was one hundred percent versus just forty-one percent in the medical management group.
The surgical group's early post-transplant survival was also non-inferior to that of three hundred and six patients without cancer who received lung transplants.
So for this very select patient group, lung transplantation was associated with longer early survival.
While broader application will need much more data, both in terms of longer term follow-up and quality of life assessments, this approach may eventually offer a new treatment option to a group of patients with historically few options.
In an accompanying editorial, Doctors Dalen and Govinda highlight both the promise and perils of this approach.
They point out that while these results are encouraging, the transplant candidates were a carefully selected subset, and any move toward wider adoption needs multi-center randomized trials, long-term outcomes, and a careful look at organ donor stewardship.
The rest of this transcript — segmented and speaker-labeled, so you land on the exact moment something was said
Search every transcript — by keyword, by phrase, or by meaning, across every show Radar indexes
Trends — what is surging across podcasts, measured against its own baseline
Alerts — when a name you follow appears in a newly indexed episode
No account is needed to search Radar.
